Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 19395317)

1.

IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.

Simpson-Abelson MR, Purohit VS, Pang WM, Iyer V, Odunsi K, Demmy TL, Yokota SJ, Loyall JL, Kelleher RJ Jr, Balu-Iyer S, Bankert RB.

Clin Immunol. 2009 Jul;132(1):71-82. doi: 10.1016/j.clim.2009.03.516. Epub 2009 Apr 22.

2.

Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells.

Chi L, Na MH, Jung HK, Vadevoo SM, Kim CW, Padmanaban G, Park TI, Park JY, Hwang I, Park KU, Liang F, Lu M, Park J, Kim IS, Lee BH.

J Control Release. 2015 Jul 10;209:327-36. doi: 10.1016/j.jconrel.2015.05.260. Epub 2015 May 12.

PMID:
25979323
3.

Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer.

Meraz IM, Savage DJ, Segura-Ibarra V, Li J, Rhudy J, Gu J, Serda RE.

Mol Pharm. 2014 Oct 6;11(10):3484-91. doi: 10.1021/mp5002697. Epub 2014 Sep 12.

PMID:
25179345
4.

Reversal of tumor immune inhibition using a chimeric cytokine receptor.

Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF.

Mol Ther. 2014 Jun;22(6):1211-20. doi: 10.1038/mt.2014.47. Epub 2014 Mar 20.

5.

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection.

Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B.

J Exp Med. 2013 Dec 16;210(13):2803-11. doi: 10.1084/jem.20130678. Epub 2013 Nov 25.

6.

Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity.

Hajdu P, Chimote AA, Thompson TH, Koo Y, Yun Y, Conforti L.

Biomaterials. 2013 Dec;34(38):10249-57. doi: 10.1016/j.biomaterials.2013.09.019. Epub 2013 Sep 27.

7.

Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.

Yokota SJ, Facciponte JG, Kelleher RJ Jr, Shultz LD, Loyall JL, Parsons RR, Odunsi K, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB.

Cancer Immun. 2013 May 31;13:11. Print 2013.

8.

Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity.

Yang L, Zaharoff DA.

Biomaterials. 2013 May;34(15):3828-36. doi: 10.1016/j.biomaterials.2013.02.031. Epub 2013 Feb 27.

9.

Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ.

Cancer Res. 2013 Mar 1;73(5):1547-58. doi: 10.1158/0008-5472.CAN-12-3343. Epub 2013 Feb 22.

10.

Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A.

J Exp Med. 2012 Dec 17;209(13):2351-65. doi: 10.1084/jem.20120944. Epub 2012 Dec 3.

11.

Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

J Immunol. 2012 Jun 15;188(12):6389-98. doi: 10.4049/jimmunol.1103019. Epub 2012 May 14. Erratum in: J Immunol. 2014 Aug 1;193(3):1513.

12.

Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.

Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA.

Clin Cancer Res. 2012 Mar 15;18(6):1672-83. doi: 10.1158/1078-0432.CCR-11-3050. Epub 2012 Jan 30.

13.

Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.

Marshall NA, Galvin KC, Corcoran AM, Boon L, Higgs R, Mills KH.

Cancer Res. 2012 Feb 1;72(3):581-91. doi: 10.1158/0008-5472.CAN-11-0307. Epub 2011 Dec 9.

14.

Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells.

Kitajima M, Ito T, Tumes DJ, Endo Y, Onodera A, Hashimoto K, Motohashi S, Yamashita M, Nishimura T, Ziegler SF, Nakayama T.

Cancer Res. 2011 Jul 15;71(14):4790-8. doi: 10.1158/0008-5472.CAN-10-1572. Epub 2011 Jun 6.

15.

Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation.

Alfaro C, Suárez N, Martínez-Forero I, Palazón A, Rouzaut A, Solano S, Feijoo E, Gúrpide A, Bolaños E, Erro L, Dubrot J, Hervás-Stubbs S, Gonzalez A, Perez-Gracia JL, Melero I.

PLoS One. 2011 Mar 14;6(3):e17922. doi: 10.1371/journal.pone.0017922.

16.

Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.

Zhang J, Zhou Z, Wang C, Shen J, Zheng Y, Zhang L, Wang J, Xia D.

Cancer Immunol Immunother. 2011 Apr;60(4):559-73. doi: 10.1007/s00262-010-0955-5. Epub 2011 Jan 15.

PMID:
21240488
17.

The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity.

Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC.

Gene Ther. 2011 May;18(5):488-95. doi: 10.1038/gt.2010.170. Epub 2011 Jan 13.

18.

Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.

Hartman ZC, Osada T, Glass O, Yang XY, Lei GJ, Lyerly HK, Clay TM.

Cancer Res. 2010 Sep 15;70(18):7209-20. doi: 10.1158/0008-5472.CAN-10-0905. Epub 2010 Sep 7.

19.

Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.

Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, Arnouk H, Su Y, Haines HL, Suarez-Cuervo C, Lamb LS Jr.

J Neurooncol. 2011 Jan;101(2):179-88. doi: 10.1007/s11060-010-0245-2. Epub 2010 Jun 10.

PMID:
20532954
20.

Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.

Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, Nakamura H, Yamanishi H, Terada N, Okamura H.

J Immunother. 2010 Apr;33(3):287-96. doi: 10.1097/CJI.0b013e3181c80ffa.

PMID:
20445349
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk